logo

CS b-Bioactive®

What is CS b-Bioactive®?

cs-moleculeCS b-Bioactive® is the most thoroughly researched chondroitin sulfate on the market. Its efficacy and safety has been tested in 20 clinical studies and more than 5,000 patients.

CS b-Bioactive® has been shown to reduce joint pain and improve mobility in people with osteoarthritis. It also slows the progression of the disease, and recent studies suggest that it reduces the need for knee replacement surgery.
  
The stringent CS b-Bioactive® manufacturing process ensures an intact, consistent molecule with unique physicochemical properties that ensure a proper absorption and efficacy.

CS b-Bioactive® is researched and manufactured by Bioibérica, the global leader in joint health.

What makes CS b-Bioactive® different from the others?

CS b-Bioactive® has unique molecular properties

Chondroitin sulfate is a non-interchangeable complex biological substance

According to the European Medicines Agency, chondroitin sulfate is a complex biological substance that cannot be interchangeable.
 

There is scientific and regulatory consensus that complex substances of biological origin exhibit significant molecular variability, depending on the manufacturing process and on the characteristics of the biological raw materials used in producing it. 
The EMA (European Medicines Agency) classifies chondroitin sulfate as a complex biological substance1 and therefore not interchangeable with other chondroitin molecules obtained from different manufacturing processes and/or from raw materials with different characteristics.

This is why, although chondroitin sulfate has been marketed as a therapeutic drug in many European countries since the early 90s, there are no generic (copied) versions of chondroitin sulfate on the market.  Any product new to the market would have to prove clinical efficacy before it could be authorized as a drug5.

CS b-Bioactive® is the active ingredient in Condrosan®, Cartexan® and Droglican®, drugs approved in Europe for the treatment of osteoarthritis and the only chondroitin on the market whose clinical efficacy has been proven in 20 controlled clinical studies and more than 5,000 patients.

 


table-csbBioactive

CS b-Bioactive®: the best-absorbed chondroitin sulfate.

Proven effective in 20 controlled clinical studies and 5,000 patients.

The CS b-Bioactive® manufacturing process guarantees unique molecular properties that ensure better absorption and efficacy.4

When comparing the permeability of different chondroitin products to that of CS b-Bioactive®, the coefficients of permeability vary widely from one tested product to another.

CS b-Bioactive® has the highest coefficient of permeability and the lowest variability, which proves the robustness of the production process and of the molecule.

The coefficient of permeability correlates with the degree of drug absorption in the human intestines.  We can therefore conclude that CS b-Bioactive® has greater absorption, which would also explain its clinical efficacy. 


CS b-Bioactive® is the safest, most effective chondroitin sulfate.

Other chondroitin products are ineffective or even cause inflammation

Some chondroitin molecules have very low efficacy, and some even produce proinflammatory effects in the joints. 2

It has been proven in proteomics studies and at the cellular level that not all chondroitins have the same pharmacological effect. 2
Compared with other chondroitins from different manufacturers, CS b-Bioactive® has demonstrated a more effective anti-inflammatory effect on the joints and greater absorption.

CS b-Bioactive® is the only chondroitin sulfate on the market that guarantees a robust, consistent molecule with physicochemical properties that result in greater efficacy and safety.

Recent publications conclude that not only are there very low-efficacy chondroitin products, but there are, more worryingly, harmful chondroitin products that cause joint inflammation.

CS b-Bioactive® is the purest, highest-quality chondroitin 

Other chondroitins are adulterated with harmful substances   

Some dietary supplements for joint health contain chondroitin that is very impure or even adulterated with health-threatening substances.

Consumer Labs, a U.S. consumer-protection organization that performs periodic independent testing of dietary supplements on the market, concluded that a large percentage of joint health dietary products contain chondroitin that is very impure or even adulterated with health-threatening substances.3

Recently, very dangerous adulterants such as sodium hexametaphosphate (Calgon®) and sodium alginate have been detected.
CS b-Bioactive® is manufactured to the highest standards of pharmaceutical manufacturing, with exhaustive controls, ensuring an ingredient of the highest quality, minimizing the presence of impurities, and exceeding the quality requirements of both the European Pharmacopoeia (EP) and the U.S. Pharmacopeia (USP).

Bioibérica also guarantees total traceability, from slaughterhouse to active ingredient.
For all these reasons, CS b-Bioactive® is the standard approved by the European Pharmacopoeia as the Chemical Reference Substance, and the U.S. National Institutes of Health (NIH) selected it for the largest osteoarthritis clinical trial, GAIT (Glucosamine/Chondroitin Arthritis Intervention Trial), due to its high quality.

1http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/procedural_guidance/Compilation_Biological_Active_Substance_non-recombinant_origin.pdf

2 Johanne Martel-Pelletier. 2015. Discrepancies in Composition and Biological Effects of Different  Formulations of Chondroitin Sulfate. Molecules 20, 4277-4289

3 http://www.consumerreports.org/cro/magazine/2013/10/facts-about-joint-supplements/index.htm

4 Abimbola O. Adebowale, Donna S. Cox, Zhongming Liang, Natalie D. Eddington. Analysis of glucosamine and chondroitin sulfate content in marketed products and the Caco-2 permeability of chondroitin sulfate raw materials. JANA 2000, Vol. 3 No. 1.

5 Vergés J, Castañeda-Hernández G. On the bioavailability of oral chondroitin sulfate formulations: proposed criteria for bioequivalence studies. Proc. West. Pharmacol. Soc. 2004, 47: 50-53 (2004).

 

Any doubt?
Contact us and we will write
you as soon as posible.

Contact